GlassScriptPhysician profile
Pradeep S Arumugham
NPI 1861495095
$4,362.12
in general payments reported to CMS, 2019-2025
26 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $149 · 2021: $680 · 2022: $914 · 2023: $974 · 2024: $419 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $26.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.52 |
| Education | $26.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $953.32 | 2019-2025 | Avvigo Guidance System, Rotablator Rotational Atherectomy System Console Kit |
| Novartis Pharmaceuticals Corporation | $634.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $558.37 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $333.66 | 2019-2025 | Lifevest |
| Abbott Laboratories | $225.27 | 2021-2023 | Cardiomems |
| Cvrx, INC. | $184.64 | 2023 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $179.55 | 2019-2025 | Brilinta, Farxiga, Andexxa |
| Janssen Pharmaceuticals, INC | $179.12 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $176.94 | 2021-2025 | Verquvo |
| Cardiovascular Systems INC. | $168.80 | 2021 | |
| Amgen INC. | $158.16 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $124.90 | 2021-2025 | Mycarelink, Linq II |
| Pfizer INC. | $109.93 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.77 | 2023-2024 | |
| Vital Connect, INC | $52.27 | 2024-2025 | Vitalpatch Rtm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $39.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.28 | 2019-2020 | |
| Novo Nordisk INC | $25.94 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.13 | 2024 | Jardiance |
| Cardiva Medical, INC. | $22.12 | 2021 | |
| Inspire Medical Systems, INC. | $21.71 | 2025 | Inspire |
| Shockwave Medical, INC | $20.96 | 2022 | |
| Chiesi USA, INC. | $17.81 | 2019 | |
| Philips North America LLC | $14.35 | 2021 | |
| Amarin Pharma, INC. | $12.81 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Arumugham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.